Ushbu ish iqtibos qilgan ishlar

199 ta ish

Ish: Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram, James Lee, Erik Hayman +4
Maqola20122 iqtibos
ABI
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru, Terence J. Purdon, David R. Spriggs +2
Maqola20152 iqtibos
ABI
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker, Michael E. Mullins, Maggie C.U. Cheang +17
Maqola20092 iqtibos
ABI
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
Stefani Spranger, Robbert M. Spaapen, Yuanyuan Zha +4
Maqola20132 iqtibos
ABI
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33
Maqola20162 iqtibos
ABI
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu, Mien‐Chie Hung
Sharh maqola20162 iqtibos
ABI
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan +80
Maqola20172 iqtibos
ABI
Tumor Heterogeneity in Breast Cancer
Gulisa Turashvili, Edi Brogi
Sharh maqola20172 iqtibos
ABI
Biomarker concordance between primary colorectal cancer and its metastases
Dilraj Bhullar, Jorge Barriuso, S. Mullamitha +3
Sharh maqola20192 iqtibos
ABI
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie +1
Sharh maqola20192 iqtibos
ABI
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38
Maqola20202 iqtibos
ABI
Memory T cells: strategies for optimizing tumor immunotherapy
Qingjun Liu, Zhongjie Sun, Ligong Chen
Sharh maqola20202 iqtibos
ABI
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner
Sharh maqola20212 iqtibos
ABI
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière +27
Maqola20212 iqtibos
ABI
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Brooke Prinzing, Caitlin C. Zebley, Christopher T. Petersen +24
Maqola20212 iqtibos
ABI
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy
Lupeng Ye, Jonathan J. Park, Lei Peng +17
Maqola20222 iqtibos
ABI
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
Jinge Zhou, Lei Sun, Yujie Jia +8
Maqola20222 iqtibos
ABI
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Zaoqu Liu, Zhaokai Zhou, Qin Dang +4
Sharh maqola20222 iqtibos
ABI
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute +4
Sharh maqola20222 iqtibos
ABI
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Ting Yan, Lingfeng Zhu, Jin Chen
Sharh maqola20232 iqtibos
ABI
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody +8
Sharh maqola20232 iqtibos
ABI
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh +4
Sharh maqola20232 iqtibos
ABI
IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey +4
Maqola20232 iqtibos
ABI
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17
Maqola20232 iqtibos
ABI
Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors
Xiuxiu Zhu, Jun Chen, Wuling Li +8
Maqola20232 iqtibos
ABI

Ushbu ish iqtibos qilgan ishlar

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i>

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Up-Regulation of PD-L1, IDO, and T <sub>regs</sub> in the Melanoma Tumor Microenvironment Is Driven by CD8 <sup>+</sup> T Cells

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Tracking the Evolution of Non–Small-Cell Lung Cancer

Tumor Heterogeneity in Breast Cancer

Biomarker concordance between primary colorectal cancer and its metastases

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

CRISPR-engineered T cells in patients with refractory cancer

Memory T cells: strategies for optimizing tumor immunotherapy

CAR-T cell therapy: current limitations and potential strategies

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy

Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models

Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors